alfuzosin has been researched along with Acute Disease in 21 studies
alfuzosin: structure given in first source
Acute Disease: Disease having a short and relatively severe course.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the efficacy of Alfuzosin XL 10 mg once daily for the acute management of acute urinary retention (AUR) with placebo in patients with benign prostatic hyperplasia (BPH) and to determine the predictors that impact this." | 9.14 | Alfuzosin 10 mg once daily increases the chances of successful trial without catheter after acute urinary retention secondary to benign prostate hyperplasia. ( Consigliere, D; Li, MK; Macalalag, M; Tibung, MJ; Tiong, HY, 2009) |
| "We confirmed the beneficial effect of the alpha1-blocker alfuzosin for the acute management of acute urinary retention (AUR) related to benign prostate hyperplasia (BPH), and further identified factors influencing the success of a trial without catheter (TWOC)." | 9.11 | Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention. ( Hargreave, TB; McNeill, SA, 2004) |
| "To study the impact of alfuzosin 10 mg once daily (OD) on the outcome of a trial without catheter (TWOC) after a first episode of acute urinary retention (AUR) related to benign prostatic hyperplasia (BPH) and the subsequent management of BPH in these patients." | 9.11 | Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study. ( Hargreave, TB; McNeill, SA; Roehrborn, CG, 2005) |
| "To study the efficiency of using alfuzosin 10 mg (Alfuprost MR, SUN Pharma) in routine clinical practice in order to predict its feasibility for treating acute urinary retention." | 7.96 | [The use of alfuzosin in the treatment of patients with acute urinary retention]. ( Ergakov, DV; Martov, AG, 2020) |
| "We analyzed the influence of treatment response on the risk of acute urinary retention and benign prostatic hyperplasia related surgery in 5,792 men complaining of lower urinary tract symptoms who were treated for 6 months with the selective alpha1-blocker alfuzosin at 10 mg once daily." | 7.73 | Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms. ( Alcaraz, A; Elhilali, M; Emberton, M; Lukacs, B; Matzkin, H; Vallancien, G, 2006) |
| "To compare the efficacy and safety of tamsulosin and alfuzosin in patients with acute urinary retention (AUR) secondary to benign prostatic hyperplasia (BPH)." | 5.19 | A comparative study on the use of tamsulosin versus alfuzosin in spontaneous micturition recovery after transurethral catheter removal in patients with benign prostatic growth. ( Carrillo-Ruiz, JD; González-Valle, JC; Guzman-Esquivel, J; Labra-Salgado, IR; Maldonado-Ávila, M; Manzanilla-García, HA; Rosas-Nava, E; Sierra-Ramírez, JA, 2014) |
| "To compare the efficacy of Alfuzosin XL 10 mg once daily for the acute management of acute urinary retention (AUR) with placebo in patients with benign prostatic hyperplasia (BPH) and to determine the predictors that impact this." | 5.14 | Alfuzosin 10 mg once daily increases the chances of successful trial without catheter after acute urinary retention secondary to benign prostate hyperplasia. ( Consigliere, D; Li, MK; Macalalag, M; Tibung, MJ; Tiong, HY, 2009) |
| "We confirmed the beneficial effect of the alpha1-blocker alfuzosin for the acute management of acute urinary retention (AUR) related to benign prostate hyperplasia (BPH), and further identified factors influencing the success of a trial without catheter (TWOC)." | 5.11 | Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention. ( Hargreave, TB; McNeill, SA, 2004) |
| "To study the impact of alfuzosin 10 mg once daily (OD) on the outcome of a trial without catheter (TWOC) after a first episode of acute urinary retention (AUR) related to benign prostatic hyperplasia (BPH) and the subsequent management of BPH in these patients." | 5.11 | Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study. ( Hargreave, TB; McNeill, SA; Roehrborn, CG, 2005) |
| "To study the efficiency of using alfuzosin 10 mg (Alfuprost MR, SUN Pharma) in routine clinical practice in order to predict its feasibility for treating acute urinary retention." | 3.96 | [The use of alfuzosin in the treatment of patients with acute urinary retention]. ( Ergakov, DV; Martov, AG, 2020) |
| "To assess the predictors of acute urinary retention (AUR) and/or surgery related to benign prostatic hyperplasia (BPH) in 3514 men complaining of lower urinary tract symptoms and treated for 6 months with the selective alpha1-blocker alfuzosin at 10 mg once daily." | 3.73 | Symptom deterioration during treatment and history of AUR are the strongest predictors for AUR and BPH-related surgery in men with LUTS treated with alfuzosin 10 mg once daily. ( Alcaraz, A; Elhilali, M; Emberton, M; Hartung, R; Harving, N; Matzkin, H; Vallancien, G; van Moorselaar, J, 2005) |
| "We analyzed the influence of treatment response on the risk of acute urinary retention and benign prostatic hyperplasia related surgery in 5,792 men complaining of lower urinary tract symptoms who were treated for 6 months with the selective alpha1-blocker alfuzosin at 10 mg once daily." | 3.73 | Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms. ( Alcaraz, A; Elhilali, M; Emberton, M; Lukacs, B; Matzkin, H; Vallancien, G, 2006) |
| "Acute urinary retention is a urological emergency in men and requires urgent catheterisation." | 2.50 | The role of alpha blockers prior to removal of urethral catheter for acute urinary retention in men. ( Fisher, E; Omar, MI; Subramonian, K, 2014) |
| "Acute urinary retention is a urological emergency in men and requires urgent catheterisation." | 2.45 | Alpha blockers prior to removal of a catheter for acute urinary retention in adult men. ( Subramonian, K; Zeif, HJ, 2009) |
| "As alfuzosin has been shown to reduce PVR, this factor may help prevent recurrent retention following TWOC." | 2.41 | Does acute urinary retention respond to alpha-blockers alone? ( McNeill, SA, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 18 (85.71) | 29.6817 |
| 2010's | 2 (9.52) | 24.3611 |
| 2020's | 1 (4.76) | 2.80 |
| Authors | Studies |
|---|---|
| Martov, AG | 1 |
| Ergakov, DV | 1 |
| Maldonado-Ávila, M | 1 |
| Manzanilla-García, HA | 1 |
| Sierra-Ramírez, JA | 1 |
| Carrillo-Ruiz, JD | 1 |
| González-Valle, JC | 1 |
| Rosas-Nava, E | 1 |
| Guzman-Esquivel, J | 1 |
| Labra-Salgado, IR | 1 |
| Fisher, E | 1 |
| Subramonian, K | 2 |
| Omar, MI | 1 |
| Tiong, HY | 1 |
| Tibung, MJ | 1 |
| Macalalag, M | 1 |
| Li, MK | 1 |
| Consigliere, D | 1 |
| Zeif, HJ | 1 |
| Shah, T | 2 |
| Palit, V | 2 |
| Biyani, S | 1 |
| Elmasry, Y | 2 |
| Puri, R | 2 |
| Flannigan, GM | 2 |
| McNeill, SA | 3 |
| Hargreave, TB | 2 |
| Yolcu, OF | 1 |
| Köklü, S | 1 |
| Köksal, AS | 1 |
| Yüksel, O | 1 |
| Beyazit, Y | 1 |
| Basar, O | 1 |
| McNeill, AS | 2 |
| Rizvi, S | 1 |
| Byrne, DJ | 1 |
| Roehrborn, CG | 1 |
| Jefferson, K | 1 |
| Okeke, A | 1 |
| Persad, R | 1 |
| Taylor, J | 1 |
| Biyani, CS | 2 |
| Browning, AJ | 1 |
| Emberton, M | 3 |
| Elhilali, M | 2 |
| Matzkin, H | 2 |
| Harving, N | 1 |
| van Moorselaar, J | 1 |
| Hartung, R | 1 |
| Alcaraz, A | 2 |
| Vallancien, G | 2 |
| Sarkar, R | 1 |
| Desgrandchamps, F | 1 |
| De La Taille, A | 1 |
| Doublet, JD | 1 |
| Lukacs, B | 1 |
| Mariappan, P | 1 |
| Brown, DJ | 1 |
| Kim, SY | 1 |
| Kim, BH | 1 |
| Dong, SH | 1 |
| Kim, HJ | 1 |
| Chang, YW | 1 |
| Chang, R | 1 |
| Kim, YW | 1 |
| Zabala, S | 1 |
| Thomson, C | 1 |
| Valdearcos, S | 1 |
| Gascón, A | 1 |
| Pina, MA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prophylactic Tamsulosin in Prevention of Post-operative Urinary Retention in Men After Transanal Endoscopic Microsurgery: A Multicenter Randomized, Double-blind, Placebo-controlled Clinical Trial[NCT03314025] | Phase 2 | 158 participants (Anticipated) | Interventional | 2017-10-06 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for alfuzosin and Acute Disease
| Article | Year |
|---|---|
The role of alpha blockers prior to removal of urethral catheter for acute urinary retention in men.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Adult; Device Removal; Doxazosin; Humans; Indoles; Male | 2014 |
Alpha blockers prior to removal of a catheter for acute urinary retention in adult men.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Adult; Device Removal; Humans; Male; Quinazolines; Rand | 2009 |
Definition of at-risk patients: dynamic variables.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Disease Progression; Humans; M | 2006 |
Does acute urinary retention respond to alpha-blockers alone?
Topics: Acute Disease; Adrenergic alpha-Antagonists; Humans; Male; Prostatic Hyperplasia; Quinazolines; Trea | 2001 |
6 trials available for alfuzosin and Acute Disease
| Article | Year |
|---|---|
A comparative study on the use of tamsulosin versus alfuzosin in spontaneous micturition recovery after transurethral catheter removal in patients with benign prostatic growth.
Topics: Acute Disease; Adrenergic alpha-1 Receptor Antagonists; Aged; Device Removal; Humans; Male; Middle A | 2014 |
Alfuzosin 10 mg once daily increases the chances of successful trial without catheter after acute urinary retention secondary to benign prostate hyperplasia.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Aged; Double-Blind Method; Humans; Male; Prostatic Hype | 2009 |
Randomised, placebo controlled, double blind study of alfuzosin SR in patients undergoing trial without catheter following acute urinary retention.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Catheterization; Delayed-Actio | 2002 |
Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Aged; Drug Administration Schedule; Humans; Male; Middl | 2004 |
Prostate size influences the outcome after presenting with acute urinary retention.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Aged; Cohort Studies; Follow-Up Studies; Humans; Male; | 2004 |
Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Aged; Biomarkers; Combined Modality Therapy; Disease-Fr | 2005 |
11 other studies available for alfuzosin and Acute Disease
| Article | Year |
|---|---|
[The use of alfuzosin in the treatment of patients with acute urinary retention].
Topics: Acute Disease; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Humans; Male; Middle Aged; Pro | 2020 |
Alfuzosin-induced acute hepatitis in a patient with chronic liver disease.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Aged, 80 and over; Chemical and Drug Induced Liver Inju | 2004 |
Re: alfuzosin once daily facilitates return to voiding in patients in acute urinary retention.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Drug Administration Schedule; Humans; Quinazolines; Uri | 2005 |
Re: Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Drug Administration Schedule; Humans; Quinazolines; Uri | 2005 |
Symptom deterioration during treatment and history of AUR are the strongest predictors for AUR and BPH-related surgery in men with LUTS treated with alfuzosin 10 mg once daily.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Drug Administration Sch | 2005 |
Long term follow up of men with Alfuzosin who voided successfully following acute urinary retention*.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Follow-Up Studies; Humans; Male; Quality of Life; Quina | 2005 |
The management of acute urinary retention in France: a cross-sectional survey in 2618 men with benign prostatic hyperplasia.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Adult; Aged; Aged, 80 and over; Catheters, Indwelling; | 2006 |
Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Aged; Drug Administration Schedule; Humans; Male; Middl | 2006 |
Intravesical prostatic protrusion is better than prostate volume in predicting the outcome of trial without catheter in white men presenting with acute urinary retention: a prospective clinical study.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Endosonography; Humans; Male; | 2007 |
Alfuzosin-induced acute liver injury.
Topics: Acute Disease; Adrenergic alpha-Antagonists; Chemical and Drug Induced Liver Injury; Dysuria; Humans | 2007 |
Alfuzosin-induced hepatotoxicity.
Topics: Acute Disease; Antihypertensive Agents; Chemical and Drug Induced Liver Injury; Humans; Hypertension | 2000 |